Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab
Related Experiment Video
Updated: Jul 5, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Dan-Yang Yang1, Wen-Wen Jing, Xin Liu
1At the Xi'an Jiaotong University and Second Affiliated Hospital, Shaanxi, China, Dan-Yang Yang, MM, Wen-Wen Jing, BM, and Xin Liu, BM, are Medical Students; Li Li, MM, and Tao Lu, MM, are Doctors; and Xiao-Li Li, PhD, is Associate Professor.
Abstract:
Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of dystrophic epidermolysis bullosa, and traditional treatments have limited efficacy. Dupilumab has demonstrated remarkable efficacy in relieving pruritus. In this case study, after traditional treatment failed, providers recommended the patient begin dupilumab to treat his pruritus. The patient was administrated a loading dose of 600 mg of dupilumab and a dose of 300 mg every 2 weeks. The Dermatology Life Quality Index and Pruritic Numeric Rating Scale were used to assess the patient's situation. After several months, the patient's DEB-Pr was considered in remission. Dupilumab may be a better choice than immunosuppressants for the treatment of pruritus in patients with DEB-Pr.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

